一项儿童神经肿瘤外科临床试验的临床与经济影响
本研究分析Re-MATCH试验(一项要求对复发髓母细胞瘤或PNET进行活检或切除的I期临床试验)对申办机构的临床与经济影响。试验入组18例患者,其中15例在申办机构手术。研究期间与非研究期间每例住院直接贡献毛利无差异,儿童脑肿瘤切除月均量从2.78例增至3.34例(增加17%),但未达统计学显著(P=0.121)。
要点
- 研究患者与非研究患者每例住院直接贡献毛利无显著差异(P=0.4819)。
- 研究期间儿童脑肿瘤切除月均3.34例,较非研究期间2.78例增加17%,但差异未达统计学显著(P=0.121)。
- I期研究者发起的以手术为基础的临床试验可能增加机构手术量而不造成经济负担。
核心结论
- I期研究者发起的以手术为基础的临床试验可能增加机构手术量而不造成经济负担,经济因素不太可能成为研究者协商资源开展此类试验的障碍。
研究设计与样本
- 本研究分析Re-MATCH试验的临床与经济影响,该试验为I期临床试验,要求对复发髓母细胞瘤或PNET进行活检或切除以入组。
- 收集试验入组3年期间及之前和之后年份的住院经济与临床工作量信息。
- 主要终点为研究患者与非研究患者直接贡献毛利(DCM)的差异,以及研究期间与非研究期间手术量的差异。
- 试验入组18例患者,其中15例在申办机构手术,3例在本地机构手术后将肿瘤材料转移至申办机构。
主要发现
- 两组在神经外科手术工作相对价值单位(P=0.13)或保险提供方(P=0.26)等潜在混杂变量上无差异。
- 非研究患者每例住院DCM(均值±标准差,9039±28549美元)与研究患者(14332±20231美元)无差异(P=0.4819)。
- 非研究期间儿童脑肿瘤切除月均2.78±1.65例,研究期间月均3.34±1.66例,增加17%。
- 排除15例研究患者后,月均2.97±1.64例,增加7%。
- 包括研究患者与非研究患者的总手术量增加未达统计学显著(P=0.121)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pediatric surgical trials are rare and the impact of such trials on the institutions in which they are conducted is unknown. The purpose of this study was to analyze the clinical and financial impact of The Re-MATCH trial, a Phase I clinical trial requiring the biopsy or resection of recurrent medulloblastoma or PNET for enrollment. Inpatient financial and clinical volume information was collected during the 3 years of trial enrollment and the years preceding and following it. The primary endpoints were the difference in direct contribution margin (DCM), or net gain, of study and non-study patients and the difference in surgical volume during the study and non-study periods. The trial enrolled 18 patients; 15 had surgery at the sponsor institution and three had surgery at their home institution, then transferred tumor material to the sponsor institution. There were no differences between the two groups for potentially confounding variables such as neurosurgical procedure work relative value units (P = 0.13) or insurance provider (P = 0.26). There was no difference between the inpatient DCM per case for the institution for non-study patients (mean ± SD, $9039 ± $28,549) and study patients ($14,332 ± $20,231) (P = 0.4819). During the non-study period, there were a mean of 2.78 ± 1.65 pediatric brain tumor resections per month compared to 3.34 ± 1.66 cases per month during the study period, a 17% increase. When the 15 study patients were excluded, there were 2.97 ± 1.64 cases per month, a 7% increase. However, this increase in total case volume including study and non-study patients was not significant (P = 0.121). Phase I investigator-initiated surgically-based clinical trials may increase institutional surgical volume without imposing a financial burden. Finances are unlikely to be a barrier for researchers negotiating for resources to conduct such trials.
引用
- Thompson EM, Gururangan S, Grant G, et al. The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial. J Neurooncol. 2016. PMID: 27864705. doi:10.1007/s11060-016-2338-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。